A polymeric scaffold contains pendant liquid crystal side chains and has fully interconnected pores. Such a polymeric scaffold will preferably be 3D in nature and elastomeric, biocompatible and biodegradable. Such 3D liquid crystal elastomer (LCE) scaffolds can be used for various biomedical applications, including cell culture applications. A method for the production of such a polymeric scaffold containing liquid crystals and having interconnected pores is also disclosed that uses a metal foam sacrificial template as a scaffold to produce the polymeric smart response scaffold of the present invention. Consistent and controlled pore sizes result from etching the sacrificial metal foam template away from the polymeric scaffold, permitting the incorporation of growth factors, when needed, for enhancing cell viability and proliferation.

The present disclosure relates to coatings containing a limus drug and an excipient, to medical devices incorporating such coatings and to methods of preparing and using such devices. In one embodiment, the limus drug is sirolimus. In another embodiment, the excipient is tannic acid or epi gallo catechin gallate.

A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto said substrate, wherein an electrical potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent.

A drug delivery balloon (10) has a drug thereon in the form of crystalline particles (12), the drug having a predetermined size distribution. Optionally marker particles (14, 16) are also provided. A texturized coating (18), a cap layer (20) and/or other methods may be used to increase particle loading capacity of the balloon.

The present application relates to the field of pharmaceutical technology, in particular, to a drug-loaded medical device, including a medical device body and at least one drug coating, the drug coating is attached to at least one side of a surface of the medical device body. The main component of the drug coating includes a macrolide drug. The drug coating includes elongated prismatic crystals each with at least three lateral edges, and/or the drug coating includes crystal clusters of the elongated prismatic crystals each with at least three lateral edges. An aspect ratio of each elongated prismatic crystal is in a range from 1:1 to 40:1.

A method for coating a medical device includes applying a second layer that includes a second drug on a first layer of on the medical device. The first layer includes a first drug, which may be in crystalline form. By selecting an appropriate solvent use in applying the second layer and appropriate process conditions, the second layer may be applied such that the first drug retains one or more therapeutic properties. For example, the second layer may be applied such that the first drug maintains its crystalline form. The first and second layers may be free of polymer.

The present invention relates to a nanoparticle composition which is prepared by a process which is characterized by dissolving a poorly water-soluble compound or the like under a high temperature and a high pressure, and milling a suspension or the like containing a uniform crystal obtained by cooling the obtained solution.

An aqueous composition of chitosan including between 0.1 and 5 wt.-% chitosan relative to the total weight of the composition, for use in increasing the volume and/or number of adipocytes. The increase in the volume and/or number of adipocytes allows for use in the treatment of or combating against ageing of the skin, for filling in skin defeats, or the repair or reconstruction of continuous or subcutaneous tissues.

A drug delivery balloon (10) has a drug thereon in the form of crystalline particles (12), the drug having a predetermined size distribution. Optionally marker particles (14, 16) are also provided. A texturized coating (18), a cap layer (20) and/or other methods may be used to increase particle loading capacity of the balloon.

Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.